- Home
- SLGL vs KAPA Comparison
SLGL vs KAPA Comparison
Compare SLGL & KAPA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLGL
- KAPA
- Stock Information
- Founded
- SLGL 1997
- KAPA 2013
- Country
- SLGL Israel
- KAPA United States
- Employees
- SLGL N/A
- KAPA N/A
- Industry
- SLGL Biotechnology: Pharmaceutical Preparations
- KAPA
- Sector
- SLGL Health Care
- KAPA
- Exchange
- SLGL Nasdaq
- KAPA NYSE
- Market Cap
- SLGL 18.3M
- KAPA 21.3M
- IPO Year
- SLGL 2018
- KAPA 2024
- Fundamental
- Price
- SLGL $0.52
- KAPA $1.71
- Analyst Decision
- SLGL Strong Buy
- KAPA Strong Buy
- Analyst Count
- SLGL 2
- KAPA 1
- Target Price
- SLGL $5.00
- KAPA $9.00
- AVG Volume (30 Days)
- SLGL 68.5K
- KAPA 720.9K
- Earning Date
- SLGL 11-15-2024
- KAPA 11-14-2024
- Dividend Yield
- SLGL N/A
- KAPA N/A
- EPS Growth
- SLGL N/A
- KAPA N/A
- EPS
- SLGL N/A
- KAPA N/A
- Revenue
- SLGL $11,707,000.00
- KAPA N/A
- Revenue This Year
- SLGL $457.85
- KAPA N/A
- Revenue Next Year
- SLGL N/A
- KAPA N/A
- P/E Ratio
- SLGL N/A
- KAPA N/A
- Revenue Growth
- SLGL 869.93
- KAPA N/A
- 52 Week Low
- SLGL $0.33
- KAPA $1.22
- 52 Week High
- SLGL $1.58
- KAPA $4.00
- Technical
- Relative Strength Index (RSI)
- SLGL 37.57
- KAPA N/A
- Support Level
- SLGL $0.40
- KAPA N/A
- Resistance Level
- SLGL $0.57
- KAPA N/A
- Average True Range (ATR)
- SLGL 0.06
- KAPA 0.00
- MACD
- SLGL -0.01
- KAPA 0.00
- Stochastic Oscillator
- SLGL 36.50
- KAPA 0.00
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline consists of silica-based microencapsulation technology platform, and several generic product candidates across multiple indications.
About KAPA KAIROS PHARMA LTD
Kairos Pharma Ltd is a clinical-stage biopharmaceutical company. It is engaged in therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma.